Spectral Medical Inc. announced the onboarding of the Mayo Clinic in Rochester, Minnesota, as its 19th clinical site for the Company's Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion ("PMX") in a randomized controlled trial of adults being treated for endotoxemia and septic shock. The Mayo Clinic is a premier medical center in the U.S. and is top ranked in more specialties than any other hospital in the nation, according to U.S. News & World Report.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.49 CAD | -2.00% | 0.00% | +15.29% |
06-07 | Transcript : Spectral Medical Inc. - Shareholder/Analyst Call | |
05-30 | Spectral Medical Closes C$8.5 Million Convertible Notes Financing | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+15.29% | 100M | |
+51.63% | 796B | |
+41.51% | 628B | |
-5.10% | 358B | |
+19.90% | 331B | |
+9.95% | 301B | |
+17.66% | 244B | |
+3.39% | 228B | |
+10.75% | 214B | |
+6.99% | 165B |
- Stock Market
- Equities
- EDT Stock
- News Spectral Medical Inc.
- Spectral Medical Inc. Announces Opening of Tigris Clinical Trial Site At the Mayo Clinic